Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • BW TV
  • Subscribe to Print

Latest Articles in drugmaker

Biocon Beefs Up Biosimilar Portfolio With $3.34 Bn Viatris Deal, Shares Fall

As per the deal, Viatris will get up to $2.34 billion in cash, and convertible shares in Biocon Biologics worth $1 billion

Read More

Moderna CEO Warns COVID-19 Shots Less Effective Against Omicron

Omicron - which the World Health Organization (WHO) said carries a "very high" risk of infection surges - has triggered global alarm, with border closures casting a shadow over a nascent economic recovery from a two-year pandemic.

Read More

Sputnik V Soft Launched In Over 50 Cities In India: Dr Reddys

The Indian drug regulator has granted permission for restricted emergency use of SputnikV, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.

Read More

Pfizer Wants To Make Vaccine In India If Faster Clearance, Export Freedom Assured

The Serum Institute of India, the world's largest vaccine maker, is already bulk-manufacturing the Oxford University/AstraZeneca product and plans to start producing the Novavax Inc shot from next month.

Read More

AstraZeneca Says It Will Have No Vaccine Supply Shortfall In Second Quarter, EU Wary

The EU official involved in talks with the company said AstraZeneca had provided no clarity on which global sites would supply the EU and whether export restrictions and regulatory issues could hamper supply.

Read More

Roche Arthritis Drug Reduces COVID-19 Deaths In Trial In Hospitalised Patients

Actemra rose to become Roche's fifth-best-selling drug, at more than $3 billion, with nearly $600 million from COVID-19 treatment.

Read More

Sanofi Eyes More Cost Cuts To Boost Profitability

Total sales rose 4.2% to 9.4 billion euros thanks to another strong revenue increase of its eczema treatment Dupixent and what it described as a "record demand" for its influenza vaccines.

Read More

McKinsey Agrees To Settle Claims Over Role In Opioid Crisis

McKinsey previously came under scrutiny for its role advising Purdue Pharma and the wealth Sackler family that owns the drugmaker.

Read More

Bharat Biotech, Ocugen Sign Pact For Supply Of Covaxin To US Market

With the recent progression of Covaxin use under EUA in India, the company is confident that it will be able to work with Ocugen to develop a plan to bring the vaccine to the US market

Read More

Pfizer Sees About $15 Billion In 2021 Sales From COVID-19 Vaccine

The vaccine was among the first to be authorized for emergency use in the United States and several other countries, and analysts have forecast billions in sales.

Read More

India's Dr.Reddy's Ends Study Of COVID-19 Drug Avigan In Kuwait

Dr.Reddy's, in partnership with GRA and Canada's Appili Therapeutics, will continue a late-stage North American trial of Avigan in patients with mild to moderate COVID-19 symptoms.

Read More

Lupin Gets USFDA Nod For Generic Diabetes Drug

As per IQVIA MAT November 2020 data, Empagliflozin and Metformin Hydrochloride ER Tablets had estimated annual sales of USD 357 million in the US.

Read More

Drugmakers To Hike Prices For 2021 As Pandemic, Political Pressure Put Revenues At Risk

Teva Pharmaceuticals Inc hiked prices on 15 drugs, including Austedo, which treats rare neurological disorders, and asthma steroid Qvar, which together grossed more than $650 million in sales in 2019 and saw price hikes of between 5% and 6%.

Read More

India Regulators Probe Alleged AstraZeneca Shot Reaction, Trial Continues

A 40-year-old man said in a complaint seen by Reuters that he had suffered serious "neurological and psychological" symptoms after receiving the vaccine in a trial being run by the British drugmaker's partner Serum Institute of India (SII).

Read More

OxyContin Maker Purdue Pharma Pleads Guilty To Criminal Charges

Purdue's plea deal carries more than $5.5 billion in penalties, most of which will go unpaid. A $3.54 billion criminal fine is set to be considered alongside trillions of dollars in unsecured claims as part of Purdue's bankruptcy proceedings.

Read More